Explore the vast range of titles available.

During September 1, 2020–April 30, 2021, the California Department of Public Health, Richmond, California, USA, received 255 positive influenza molecular test results that matched with severe acute respiratory syndrome coronavirus 2 molecular test results; 58 (23%) persons were co-infected. Influenza activity was minimal in California, and co-infections were sporadic.

We investigated whether a public health-oriented Problem-Based Learning case presented to first-year medical students conveyed 12 “Population Health Competencies for Medical Students,” as recommended by the Association of American Medical Colleges and the Regional Medicine-Public Health Education Centers. A public health-oriented Problem-Based Learning case guided by the ecological model paradigm was developed and implemented among two groups of 8 students at the University of California, Berkeley-UCSF Joint Medical Program, in the Fall of 2010. Using directed content analysis, student-generated written reports were coded for the presence of the 12 population health content areas. Students generated a total of 29 reports, of which 20 (69%) contained information relevant to at least one of the 12 population health competencies. Each of the 12 content areas was addressed by at least one report. As physicians-in-training prepare to confront the challenges of integrating prevention and population health with clinical practice, Problem-Based Learning is a promising tool to enhance medical students’ engagement with public health.

In 2023, adults ≥60 years old were eligible to receive updated influenza and COVID-19 vaccines along with newly available respiratory syncytial virus (RSV) vaccines. Vaccine acceptance for influenza is typically high among this age cohort. We assessed COVID-19 and RSV vaccine uptake among influenza vaccine recipients to identify sociodemographic disparities among California adults ≥60 years old who did not receive all three vaccinations. We used a cross-sectional design to assess the prevalence of COVID-19 and RSV vaccination among California adults ≥60 years old with an influenza vaccination reported to the California Immunization Registry during 08/01/2023–06/30/2024. We used log binomial regression to calculate prevalence ratios (PR) and 95 % confidence intervals (95 %CI) that measured associations between recipient sociodemographic characteristics and receipt of all three vaccines. Among 4,471,042 adults included in this study, 901,815 (20 %) received all three vaccinations during 2023–2024. The prevalence for receiving COVID-19 and RSV vaccines among Latino adults residing in the lowest resource communities was 80 % less (PR: 0.20, 95 %CI: 0.19, 0.20) than among white adults residing in the highest resource communities when the vaccination status of the comparison group was limited to influenza only vaccine recipients. We identified concerning disparities in the uptake of COVID-19 and RSV vaccines among older adults during the 2023–2024 respiratory virus season in California. Provider awareness of these disparities may help improve vaccine uptake among older adult populations when patients seek their seasonal influenza vaccinations.

IntroductionThe COVID-19 Claims Reimbursement for Vaccine Administration for the Uninsured Programme (COVID-19 Uninsured Programme), a novel, short-term federal initiative, reimbursed providers for healthcare-related expenses incurred through the vaccination of individuals without healthcare coverage. The present study aimed to characterise the use of the COVID-19 Uninsured Programme in California and estimate the effect of the end of the programme on vaccine administration.MethodsCalifornia vaccine providers who received reimbursements through 5 April 2022 (the programme end date) were linked to providers in the state immunisation registry. Generalised synthetic control methods were used to estimate the effect of the end of the programme on COVID-19 vaccine administration rates during the ensuing 8 weeks in counties with the highest (>3%) versus lowest (<1%) proportion of doses reimbursed.ResultsOverall, 1145 vaccine providers across 48 of California’s 58 counties received reimbursement through the COVID-19 Uninsured Programme. The county-level median number and percentage of doses reimbursed through the programme was 2908 (IQR=406–18 578) and 0.9% (IQR=0.4%–2.5%), respectively. Among the 8 counties with the greatest proportion of doses reimbursed, an estimated 6.4 fewer doses were administered per 10 000 vaccine-eligible residents per day (95% CI: −10.4 to −2.5).ConclusionsThe end of the COVID-19 Uninsured Programme was associated with lower vaccine administration rates among counties with high participation in the programme; several counties had low or no participation in the programme, indicating underutilisation.

Despite lower circulation of influenza virus throughout 2020–2022 during the COVID-19 pandemic, seasonal influenza vaccination has remained a primary tool to reduce influenza-associated illness and death. The relationship between the decision to receive a COVID-19 vaccine and/or an influenza vaccine is not well understood. We assessed predictors of receipt of 2021–2022 influenza vaccine in a secondary analysis of data from a case-control study enrolling individuals who received SARS-CoV-2 testing. We used mixed effects logistic regression to estimate factors associated with receipt of seasonal influenza vaccine. We also constructed multinomial adjusted marginal probability models of being vaccinated for COVID-19 only, seasonal influenza only, or both as compared with receipt of neither vaccination. Among 1261 eligible participants recruited between 22 October 2021–22 June 2022, 43% (545) were vaccinated with both seasonal influenza vaccine and >1 dose of a COVID-19 vaccine, 34% (426) received >1 dose of a COVID-19 vaccine only, 4% (49) received seasonal influenza vaccine only, and 19% (241) received neither vaccine. Receipt of >1 COVID-19 vaccine dose was associated with seasonal influenza vaccination (adjusted odds ratio [aOR]: 3.72; 95% confidence interval [CI]: 2.15–6.43); this association was stronger among participants receiving >1 COVID-19 booster dose (aOR = 16.50 [10.10–26.97]). Compared with participants testing negative for SARS- CoV-2 infection, participants testing positive had lower odds of receipt of 2021-2022 seasonal influenza vaccine (aOR = 0.64 [0.50–0.82]). Recipients of a COVID-19 vaccine were more likely to receive seasonal influenza vaccine during the 2021–2022 season. Factors associated with individuals’ likelihood of receiving COVID-19 and seasonal influenza vaccines will be important to account for in future studies of vaccine effectiveness against both conditions. Participants who tested positive for SARS-CoV-2 in our sample were less likely to have received seasonal influenza vaccine, suggesting an opportunity to offer influenza vaccination before or after a COVID-19 diagnosis.

Surveillance data can provide rapid, within-season influenza vaccine effectiveness (VE) estimates to guide public health recommendations. Mandatory reporting of influenza vaccine administration to California's immunization information registry began January 1, 2023, and mandatory reporting of all influenza laboratory test results, including negative results, was instituted in California on June 15, 2023. These data, collected by the California Department of Public Health during October 1, 2023-January 31, 2024, were used to calculate interim influenza VE against laboratory-confirmed influenza by comparing the odds of vaccination among case-patients (persons who received a positive influenza laboratory test result) and control patients (those who received a negative influenza laboratory test result). VE was calculated as 1 - adjusted odds ratio using mixed-effects logistic regression, with age, race, and ethnicity as fixed effects and specimen collection week and county as random effects. Overall, during October 1, 2023-January 31, 2024, estimated VE was 45% among persons aged ≥6 months, 56% among children and adolescents aged 6 months-17 years, 48% among adults aged 18-49 years, 36% among those aged 50-64 years, and 30% among those aged ≥65 years. Consistent with some previous influenza seasons, influenza vaccination provided moderate protection against laboratory-confirmed influenza among infants, children, adolescents, and adults. All persons aged ≥6 months without a contraindication to vaccination should receive annual influenza vaccination to reduce influenza illness, severe influenza, and strain on health care resources. Influenza vaccination remains the best way to prevent influenza.

Persons who work closely with dairy cows, poultry, or other animals with suspected or confirmed infection with highly pathogenic avian influenza (HPAI) A(H5N1) viruses are at increased risk for infection. In September 2024, the California Department of Public Health was notified of the first human case of HPAI A(H5N1) in California through monitoring of workers on farms with infected cows. During September 30-December 24, 2024, a total of 38 persons received positive test results for HPAI A(H5N1) viruses in California; 37 were dairy farm workers with occupational exposure to sick cows, and one was a child aged <18 years with an undetermined exposure, the first pediatric HPAI A(H5N1) case reported in the United States. All patients had mild illness. The identification of cases associated with occupational exposure to HPAI A(H5N1) viruses on dairy farms highlights the continued risk for persons who work with infected animals. The pediatric case was identified through routine surveillance. Given recent increases in the prevalence of HPAI A(H5N1) viruses among some animal populations, public health agencies should continue to investigate cases of HPAI A(H5N1) in humans as part of control measures, pandemic preparedness, to identify concerning genetic changes, and to prevent and detect potential human-to-human transmission of the virus. To date, no human-to-human transmission of HPAI A(H5N1) virus has been identified in the United States.

In December 2014, PulseNet, the national molecular subtyping network for foodborne disease, detected a multistate cluster of Shigella sonnei infections with an uncommon pulsed-field gel electrophoresis (PFGE) pattern. CDC's National Antimicrobial Resistance Monitoring System (NARMS) laboratory determined that isolates from this cluster were resistant to ciprofloxacin, the antimicrobial medication recommended to treat adults with shigellosis. To understand the scope of the outbreak and to try to identify its source, CDC and state and local health departments conducted epidemiologic and laboratory investigations. During May 2014-February 2015, PulseNet identified 157 cases in 32 states and Puerto Rico; approximately half were associated with international travel. Nine of the cases identified by PulseNet, and another 86 cases without PFGE data, were part of a related outbreak of ciprofloxacin-resistant shigellosis in San Francisco, California. Of 126 total isolates with antimicrobial susceptibility information, 109 (87%) were nonsusceptible to ciprofloxacin (108 were resistant, and one had intermediate susceptibility). Travelers need to be aware of the risks of acquiring multidrug-resistant pathogens, carefully wash their hands, and adhere to food and water precautions during international travel. Clinicians should request stool cultures and antimicrobial susceptibilities when they suspect shigellosis, and counsel shigellosis patients to follow meticulous hygiene regimens while ill.